PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRSOS, Martin L; KOKER, Mirjam; MICHEL, Kathrin et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 8, pp 3256-3261, issn 0008-5472, 6 p.Article

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK InhibitorsHEUCKMANN, Johannes M; HÖLZEL, Michael; RAUH, Daniel et al.Clinical cancer research (Print). 2011, Vol 17, Num 23, pp 7394-7401, issn 1078-0432, 8 p.Article

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerPEIFER, Martin; FERNANDEZ-CUESTA, Lynnette; MENON, Roopika et al.Nature genetics. 2012, Vol 44, Num 10, pp 1104-1110, issn 1061-4036, 7 p.Article

Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance MutationSOS, Martin L; RODE, Haridas B; RUDDIGKEIT, Lars et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 3, pp 868-874, issn 0008-5472, 7 p.Article